Skip to main content
. Author manuscript; available in PMC: 2011 Mar 17.
Published in final edited form as: Neuroscience. 2009 Dec 24;166(2):712–719. doi: 10.1016/j.neuroscience.2009.12.036

Table 2.

Demographics of Parkinson’s disease subjects in this study

Subject # Age at baseline (yr) Handed-ness Presenting symptoms Scan interval (mo) UPDRS-III scores in “off” stage Antiparkinson drugs at baseline* Antiparkinson drugs at follow-up
Baseline Follow-up
1 52 Right Decreased arm swing and left hand dexterity 22 2 3 Pramipexole 1.5 tid Carbidopa/Levodopa/Entacapone 50 tid
Pramipexole 1 tid
Selegiline 5 bid
2 58 Right Tenseness and decreased left hand dexterity. 21 3 3 Carbidopa/Levodopa 25/100 tid Carbidopa/Levodopa 25/100 tid; 37.5/150 qam
3 50 Right Postural tremor of right hand. 27 4 4.5 Pramipexole 0.5 tid Pramipexole 0.5 tid
Selegiline 5 bid
4 55 Right Stiffness and decreased right hand dexterity. 20 6 7.5 Pramipexole 1.5 tid Pramipexole 1.5 tid
Selegiline 5 bid
5 71 Right Right hand resting tremor. 24 7 10.5 Carbidopa/Levodopa/Entacapone 50 tid Pramipexole 0.375 tid Pramipexole 1.5 t.i.d
Selegiline 5 bid
*

Doses are in mg except as noted; qam=every morning; bid = twice a day; tid = three times a day